MNEXSPIKE Disease Interactions
There are 3 disease interactions with mNEXSPIKE (COVID-19 mRNA (Moderna) vaccine).
COVID-19 vaccine, mRNA (applies to mNEXSPIKE) immunodeficiency
Moderate Potential Hazard, Moderate plausibility.
Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to the messenger RNA COVID-19 vaccine. The US CDC has published considerations related to COVID-19 vaccination for individuals who are moderately to severely immunocompromised (https://www.cdc.gov/covid/hcp/vaccine-considerations/).
COVID-19 vaccine, mRNA (applies to mNEXSPIKE) syncope
Moderate Potential Hazard, Moderate plausibility.
Syncope may occur in association with administration of injectable vaccines, including the messenger RNA COVID-19 vaccine. Procedures should be in place to avoid injury from fainting, especially for patients who have previously fainted in association with an injection.
Vaccines (applies to mNEXSPIKE) IM injection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopathy, Thrombocytopenia, Coagulation Defect
In patients with thrombocytopenia or coagulation disorders, IM injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine; hepatitis A and B vaccines; aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered IM. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.
Switch to professional interaction data
MNEXSPIKE drug interactions
There are 351 drug interactions with mNEXSPIKE (COVID-19 mRNA (Moderna) vaccine).
Report options
More about mNEXSPIKE (COVID-19 mRNA (Moderna) vaccine)
- Check interactions
- Compare alternatives
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: viral vaccines
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.